消痤灵颗粒抗菌及其对丙酸杆菌致大鼠耳廓炎症痤疮的防治作用

目的 :研究消痤灵颗粒体外抑菌作用及对痤疮模型的疗效。方法 :用琼脂倾注平板法测定消痤灵颗粒体外MIC、MIC50 、MBC和MBC50 ,用内耳廓皮内注射丙酸杆菌建立大鼠耳廓炎症痤疮模型 ,观察用药前后痤疮模型的大体及镜下改变。结果 :消痤灵颗粒抑制体外金黄色葡萄球菌 (金葡菌 )、白色葡萄球菌 (白葡菌 )及丙酸杆菌的生长 ,减轻或消除大鼠耳廓痤疮模型的炎性肿胀。结论 :消痤灵颗粒对痤疮有抑菌和防治作用     

自体骨钉治疗关节软骨及软骨下骨折

目的 观察自体骨钉内固定治疗关节软骨及软骨下骨折的疗效。方法 采用自体骨钉固定治疗关节软骨及软骨下骨折３８例,按骨折愈合、关节面平整程序、关节疼痛、活动范围、生活质量等指标积分评价疗效。结果 ３８例随访６￣３４个月,结果优２８例,良８例,可１例,差１例,优良率为９４．７％。结论 自同钉内固定是治疗关节有及软同钉内有下骨折的良好方法。     

肿瘤相关基因SNC90 cDNA真核细胞表达型重组质粒的构建及其转染研究 *

目的:构建肿瘤相关基因SNC90哺乳动物细胞表达型载体并进行转染研究.方法:肿瘤相关基因SNC90cDNA片断亚克隆至哺乳动物细胞表达型质粒pREP9中,并运用脂质体和电穿孔法将重组质粒pREP9-SN90转入3株人大肠癌细胞中,用G418筛选抗性细胞克隆.结果:重组体pREP9-SN90对SW1116,COLO205和SW620肠癌细胞株克隆形成均有一定的抑制作用,抑制率分别为72.2%,74.2%和59.7%.结论:这提示肿瘤相关基因SNC90对肠癌细胞生长起负性调节作用.     

Folate Deficiency Decreases Apoptosis of Endometrium Decidual Cells in Pregnant Mice via the Mitochondrial Pathway

It is well known that maternal folate deficiency results in adverse pregnancy outcomes. In addition to aspects in embryonic development, maternal uterine receptivity and the decidualization of stromal cells is also very important for a successful pregnancy. In this study, we focused on endometrium decidualization and investigated whether apoptosis, which is essential for decidualization, was impaired. Flow cytometry and TUNEL detection revealed that apoptosis of mouse endometrium decidual cells was suppressed in the dietary folate-deficient group on Days 7 and 8 of pregnancy (Day 1 = vaginal plug) when decidua regression is initiated. The endometrium decidual tissue of the folate deficiency group expressed less Bax compared to the normal diet group while they had nearly equal expression of Bcl2 protein. Further examination revealed that the mitochondrial transmembrane potential (ΔΨm) decreased, and the fluorescence of diffuse cytoplasmic cytochrome c protein was detected using laser confocal microscopy in normal decidual cells. However, no corresponding changes were observed in the folate-deficient group. Western blotting analyses confirmed that more cytochrome c was released from mitochondria in normal decidual cells. Taken together, these results demonstrated that folate deficiency could inhibit apoptosis of decidual cells via the mitochondrial apoptosis pathway, thereby restraining decidualization of the endometrium and further impairing pregnancy.     

Circulating sortilin levels are associated with inflammation in patients with moyamoya disease

Metabolic Brain Disease - Systemic inflammation has been implicated in the pathogenesis of moyamoya disease (MMD). Sortilin is a critical regulator of proinflammatory cytokine secretion in several...     

外周血循环肿瘤DNA检测方法及应用

肿瘤是一种威胁人类健康的重大疾病。研究发现,肿瘤的发生和发展是基于分子水平上癌基因(oncogenes)的激活和抑癌基因(anti-oncogene)的失活所致。基因突变分析对于肿瘤诊断和预后至关重要。早期诊断被认为是提高癌症病人治愈率,降低其死亡率最有效的途径。外周血循环肿瘤核酸中可检测到与肿瘤细胞一致的基因突变。这些基因突变的检测可以为肿瘤的分期及药物的治疗疗效和预后提供丰富的信息。因此,外周血循环肿瘤DNA突变检测为肿瘤的早期诊断和治疗提供了新的研究方向和领域。     

The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis

Cerebral venous sinus thrombosis (CVST) is an uncommon subtype of stroke with highly variable clinical presentation. Although anticoagulation with heparin and/or warfarin remains the standard treatment for CVST, treatment failure is still common. This study aims to evaluate the safety and efficacy of Batroxobin in combination with anticoagulation on CVST control. In this retrospective study, a total of 61 CVST patients were enrolled and divided into Batroxobin (n?=?23) and control (n?=?38) groups. In addition to the same standard anticoagulation in control, patients in the treatment group received Batroxobin 5 BU intravenous infusion (10 BU for the first time) every other day, for a total of three infusions. A higher recanalization rate was found in Batroxobin group (adjusted OR [95% CI] of 2.5 [1.1–5.0], p?=?0.028) compared to the control group, especially in patients with high levels of fibrinogen (adjusted OR [95% CI] of 4.7 [1.4–16.7], p?=?0.015). Statistically significant differences between the two groups were seen regarding the levels of thrombin time, fibrinogen and d-dimer at each cut-off time point (all p?<?0.01). Compared with baseline, NIHSS scores at discharge showed significant improvement in the Batroxobin group [0(0, 4.25)–5(2, 11), p?=?0.036]. No significant difference in mRS scores was found between the two groups at discharge or at 6-month outpatient follow-up (all p?>?0.05). Additionally, Batroxobin did not increase the risk of intracranial hemorrhage. We conclude that Batroxobin is a potentially safe and effective adjunct therapeutic agent promoting CVST recanalization especially in patients with high level of fibrinogen.